Shanghai, China — MicroPort^® CardioFlow Medtech Corporation (02160.HK, "MicroPort^® CardioFlow") recently announced that its VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System ("VitaFlow Liberty^®") and Alwide^® PlusAlwide^® Plus Balloon Catheter  ("Alwide^® Plus") have received registration approval from the Ministry of Healthcare of the Republic of Kazakhstan (Registration No.: ҚР-МБ (ММБ)-0№029027/ҚР-МБ (ММБ)-0№028972).

VitaFlow Liberty^®, the world’s first electric-retrievable TAVI (Transcatheter Aortic Valve Implantation) product, was approved by China’s National Medical Products Administration (NMPA) in 2021 and has since entered multiple overseas markets. In 2024, it became the first China-made TAVI system to obtain EU CE MDR certification. VitaFlow Liberty^® inherits the advantages of its predecessor, VitaFlow^®, in terms of valve design, featuring a hybrid density self-expanding stent, bovine pericardial leaflets, and an advanced double-layer PET skirt. These design elements offer strong radial support, improved coaxial deployment, and reduced perivalvular leakage post-procedure. Moreover, its breakthrough next-generation delivery system incorporates a unique and innovative double-reinforced spiral structure that ensures rapid, stable, and precise release and retrieval. This system also provides flexibility, allowing for 360-degree bending of the valve segment.

Alwide^® Plus, a companion product for TAVI procedures, received NMPA approval in 2021 and is currently progressing toward EU CE MDR certification. Its ultra-low compliance can realize more precise balloon expansion to avoid vascular damage, high burst pressure performance can effectively expand the site of severe calcification, fast filling and pumping performance can minimize the impact of prolonged blood flow blockage on cardiac function, reduce the pacing time, and lower the risk of surgery, significantly improved anti-puncture performance can further increase the safety of balloon dilatation while bring the physicians a better experience.

With proven clinical performance, MicroPort^® CardioFlow’s global expansion has achieved remarkable success. To date, its VitaFlow^® TAVI series and Alwide^® balloon products have been adopted in over 700 leading hospitals across over 20 countries/regions, treating over 10,000 aortic valve disease patients worldwide.

Kazakhstan, the largest and most economically advanced country in Central Asia, is experiencing robust growth in its medical device market due to healthcare reforms and infrastructure upgrades. The approval of VitaFlow Liberty^® and Alwide^® Plus marks a strategic milestone in MicroPort^® CardioFlow's Asia-Pacific expansion, further solidifying its global footprint to benefit more structural heart disease patients.